Clinical trial
Emerging Indications for Hyperbaric Oxygen Treatment
NCT07240649 is registered in ClinicalTrials.gov with Jay C. Buckey Jr. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Emerging Indications for Hyperbaric Oxygen Treatment
- Lead sponsor
- Jay C. Buckey Jr.
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- December 31, 2035
- Enrollment
- 100 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
acute covid-19, anastomosis, leaking, avascular necrosis of bone, axonotmesis, branch retinal artery occlusion, calciphylaxis, cartilage injury, central retinal vein occlusion, chronic anal fissure, clostridium enterocolitis, crohn disease, cystitis chronic, decubitus ulcer, epidermolysis bullosa (eb), facial filler injections, femoral head necrosis, frostbite, graft-vs-host disease, greater trochanteric pain syndrome, head trauma, hypospadias, inclusion body myositis, invasive fungal infection, ischemic bowel, ligament injury, malignant otitis externa, multiple sclerosis, nonarteritic anterior ischemic optic neuropathy, osteonecrosis, pneumatosis intestinalis, post-covid-19 condition, pouchitis, prosthesis related infections, pterygium, pyoderma gangrenosum, raynaud syndrome, rectovaginal fistula, tinnitus, ulcer ischemic, ulcerative colitis, vasculitic ulcer